$0.35
0.84% yesterday
NYSE, Sep 27, 10:15 pm CET
ISIN
US81727U1051
Symbol
SENS

Senseonics Stock price

$0.35
-0.05 13.54% 1M
-0.21 38.02% 6M
-0.22 38.73% YTD
-0.19 35.60% 1Y
-3.25 90.30% 3Y
-0.65 65.07% 5Y
-2.90 89.25% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.00 0.84%
ISIN
US81727U1051
Symbol
SENS
Sector

Key metrics

Market capitalization $185.52m
Enterprise Value $197.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.21
P/S ratio (TTM) P/S ratio 7.72
P/B ratio (TTM) P/B ratio 320.74
Revenue growth (TTM) Revenue growth 30.25%
Revenue (TTM) Revenue $24.04m
EBIT (operating result TTM) EBIT $-73.75m
Free Cash Flow (TTM) Free Cash Flow $-66.44m
Cash position $84.95m
EPS (TTM) EPS $-0.14
P/E forward negative
P/S forward 8.36
EV/Sales forward 8.90
Short interest 9.00%
Show more

Is Senseonics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Senseonics Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Senseonics forecast:

2x Buy
40%
1x Hold
20%
2x Sell
40%

Analyst Opinions

5 Analysts have issued a Senseonics forecast:

Buy
40%
Hold
20%
Sell
40%

Financial data from Senseonics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
24 24
30% 30%
100%
- Direct Costs 21 21
30% 30%
88%
2.89 2.89
31% 31%
12%
- Selling and Administrative Expenses 31 31
4% 4%
127%
- Research and Development Expense 45 45
6% 6%
186%
-72 -72
4% 4%
-301%
- Depreciation and Amortization 1.34 1.34
46% 46%
6%
EBIT (Operating Income) EBIT -74 -74
3% 3%
-307%
Net Profit -80 -80
18% 18%
-335%

In millions USD.

Don't miss a Thing! We will send you all news about Senseonics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Senseonics Stock News

Neutral
Business Wire
11 days ago
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the US Food and Drug Administration (FDA) has...
Neutral
GlobeNewsWire
11 days ago
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system  for people with diabetes
Neutral
GlobeNewsWire
21 days ago
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, being held in N...
More Senseonics News

Company Profile

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Head office United States
CEO Timothy Goodnow
Employees 132
Founded 2014
Website www.senseonics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today